GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Price-to-Owner-Earnings

PLx Pharma Winddown (PLx Pharma Winddown) Price-to-Owner-Earnings : (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Price-to-Owner-Earnings?

As of today (2024-04-29), PLx Pharma Winddown's share price is $0.0002. PLx Pharma Winddown does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for PLx Pharma Winddown's Price-to-Owner-Earnings or its related term are showing as below:


PLXPQ's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.82
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), PLx Pharma Winddown's share price is $0.0002. PLx Pharma Winddown's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.85. Therefore, PLx Pharma Winddown's PE Ratio for today is At Loss.

As of today (2024-04-29), PLx Pharma Winddown's share price is $0.0002. PLx Pharma Winddown's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.17. Therefore, PLx Pharma Winddown's PE Ratio without NRI for today is At Loss.


PLx Pharma Winddown Price-to-Owner-Earnings Historical Data

The historical data trend for PLx Pharma Winddown's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Winddown Price-to-Owner-Earnings Chart

PLx Pharma Winddown Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 17.19 - - -

PLx Pharma Winddown Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PLx Pharma Winddown's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma Winddown's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma Winddown's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma Winddown's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where PLx Pharma Winddown's Price-to-Owner-Earnings falls into.



PLx Pharma Winddown Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

PLx Pharma Winddown's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0002/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PLx Pharma Winddown  (OTCPK:PLXPQ) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


PLx Pharma Winddown Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.
Executives
Rita M O'connor officer: Chief Financial Officer 4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano director, officer: Chief Executive Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino director, officer: Executive Chairman 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden director 1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh director C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman officer: Chief Operating Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden officer: Acting Chief Financial Officer 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381

PLx Pharma Winddown (PLx Pharma Winddown) Headlines